business
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
Key takeaways
- Transaction value based on SEC Form 4 weighted average purchase price ($110.73).
- What does the 100.00% direct holdings sale indicate in the context of prior trading activity?This action completes a sequence of option exercises and immediate sales.
- Palvella Therapeutics develops and advances QTORIN rapamycin, a topical gel for rare dermatological conditions.
PVLA Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (NASDAQ:PVLA), reported the exercise of 4,302 stock options immediately converted and sold as common shares for a transaction value of approximately $476,000 according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($110.73).
How does this transaction impact Goin's overall exposure to Palvella Therapeutics?While direct ownership of common stock is now zero, Goin maintains 17,219 options outstanding (direct), preserving her economic interest via potential future share conversion.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop